OakChart

Tvardi Therapeutics Inc

TVRDHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 9:25 AM ET

1.42+0.01 (0.40%)
2026-11-11 15:30 CET
Market cap
18.81 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-26.06 USD m
Free cash flow, TTM
-25.03 USD m
EPS diluted, TTM
-2.78
P/E
-
Compare

Price

TVRD against its 20, 50 and 200-day averages
2050200miss
2.505.007.5010.0035.4M70.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TVRDclose 1.4220-day 0.9950-day 1.26200-day 2.621.42

75.1% under 5.69 on 8 Jul 2026. Last 15 sessions, 108.3% high to low

Profile

TVRD
52-week range, 13% of the way up
0.775.69

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company was founded in 2017 and is headquartered in Sugar Land, TX.

Employees12
IPOJan 31, 2014
Beta0.22
ATR, 14d0.14
Rel volume0.73
Short float2.98%
Insider own24.71%
Inst own17.00%

Snapshot

6 groups

Valuation

Index-
Market Cap18.88M
Enterprise Value3.25M
Income-26.06M
Sales0.00M
Book/sh0.89
Cash/sh1.18
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees12
IPOJan 31, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.58
P/C1.20
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio1.87
Current Ratio1.87
Debt/Eq0.02
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-2.78
EPS next Y-2.18
EPS next Q-0.57
EPS this Y31.66%
EPS next Y1.96%
EPS next 5Y1.03%
EPS past 3/5Y61.55% -
Sales past 3/5Y- -
EPS Y/Y TTM82.57%
Sales Y/Y TTM-100.00%
EPS Q/Q31.47%
Sales Q/Q-
EarningsAug 14 BMO
EPS/Sales Surpr.2.04% -

Ownership

Insider Own24.71%
Insider Trans0.00%
Inst Own17.00%
Inst Trans-12.12%
ROA-85.08%
ROE-126.19%
ROIC-310.13%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2043.10%
SMA5012.17%
SMA200-45.96%
Trades-

Technical

Shs Outstand13.34M
Shs Float10.04M
Short Float2.98%
Short Ratio1.25
Short Interest0.30M
52W High5.69 -75.12%
52W Low0.77 83.15%
Volatility23.99% 13.05%
ATR (14)0.14
RSI (14)68.83
Beta0.22
Rel Volume0.73
Avg Volume239.43K
Volume8,684

Performance

Perf Week64.34%
Perf Month36.12%
Perf Quarter-20.02%
Perf Half Y-64.16%
Perf YTD-67.08%
Perf Year-66.21%
Perf 3Y-96.26%
Perf 5Y-99.76%
Perf 10Y-99.58%
Recom1.78
Target Price9.62
Prev Close1.41
Price1.42
Change %0.40%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 20, 2026InitiatedCChardan Capital MarketsBuy$8+465.1%
Jul 08, 2026UpgradeRRaymond JamesMkt Perform → Outperform$10+606.4%
Jul 08, 2026UpgradePPiper SandlerNeutral → Overweight$13+818.3%
Jun 08, 2026InitiatedHH.C. WainwrightBuy$9+535.8%
Apr 20, 2026DowngradeBBarclaysEqual Weight → Underweight$3+111.9%
Oct 14, 2025DowngradeRRaymond JamesOutperform → Mkt Perform
Oct 14, 2025DowngradeBBarclaysOverweight → Equal Weight$5+253.2%
Oct 13, 2025InitiatedBBarclaysOverweight$61+4,209.1%
Oct 13, 2025DowngradePPiper SandlerOverweight → Neutral$78 → $4+182.6%
Oct 13, 2025DowngradeCCantor FitzgeraldOverweight → Neutral

Peers

Mkt cap
TickerCompanyMkt cap
PALIPalisade Bio Inc195.19M
PLRXPliant Therapeutics Inc48.65M
ABVXAbivax ADR7.98B
CNTBConnect Biopharma Holdings Ltd43.43M
ACRSAclaris Therapeutics Inc620.17M
ALMSAlumis Inc862.38M
MCRBSeres Therapeutics Inc16.95M
SYRESpyre Therapeutics Inc9.92B
TPSTTempest Therapeutics Inc8.48M
CLRBCellectar Biosciences Inc11.81M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 206
  • Tvardi Therapeutics to Participate in Chardan's 10th Annual Healthcare Conference (GlobeNewswire)
  • New Preclinical Data Further Support Potential for Tvardi's STAT3 Inhibitors in Ulcerative Colitis (UC) (GlobeNewswire) -19.70%
  • Tvardi Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire)
  • Tvardi: Q2 Earnings Snapshot (Associated Press) +7.34%
  • Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update (GlobeNewswire)
  • Loading…
  • Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026 (GlobeNewswire)
  • Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109 (GlobeNewswire)
  • Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement (GlobeNewswire) +54.23%
  • Tvardi Therapeutics to Participate in Upcoming Investor Events (GlobeNewswire) -6.75%
  • Tvardi: Q1 Earnings Snapshot (Associated Press)
  • Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update (GlobeNewswire)
  • Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium (GlobeNewswire)
  • Tvardi: Q4 Earnings Snapshot (Associated Press) -5.66%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-14-0.690-0.704-0.6880.000.009
2026Q12026-05-08-0.730-0.744-0.7250.000.007
2025Q42026-03-31-0.780-0.646-0.7760.000.008
2025Q32025-11-13-0.590-1.000-0.5890.000.008
2025Q22025-08-14-1.000-0.683-1.0040.000.006
2025Q12025-05-13-3.220-0.585-3.2192.570.002
2024Q12024-05-13-20.160-14.328-20.2442.141.685
2023Q42024-03-04-21.240-16.056-21.3693.009.425
2023Q32023-11-13-18.720-18.720-18.6074.909.956
2023Q22023-08-07-20.880-19.379-20.9856.936.506
2023Q12023-05-15-17.640-18.482-17.8196.174.897
2022Q42023-03-06-20.160-12.344-20.3153.2614.507
2022Q32022-11-07-15.480-14.810-15.53210.818.847
2022Q22022-08-08-2.880-9.410-2.82423.0021.117
2022Q12022-05-09-18.720-19.850-18.6704.792.647
2021Q42022-03-01-22.680-18.410-22.7790.821.467

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-89.640-91.879-89.74719.8920.74
2020FY6.480-43.7876.319135.0828.07
2021FY-62.640-60.066-62.77523.0323.35
2022FY-57.240-48.737-57.35141.8753.45
2023FY-78.840-72.216-78.79120.9727.41
2024FY-1.530--11.4200.00-
2025FY-3.260-2.230-3.2600.000.37
2026FY--2.228--0.00
2027FY--2.184--0.00
2028FY--3.160--0.00
2029FY--3.171--9.46
2030FY--3.102--17.17

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-168000.000.000.00
2026Q3S2026-09-047000.000.000.00
2026Q3S2026-08-276000.000.000.00
2026Q3S2026-08-166000.000.000.00
2026Q3S2026-08-147000.000.000.00
2026Q3S2026-06-057000.000.000.00
2026Q3S2026-05-086000.000.000.00
2026Q3S2026-04-145000.000.000.00
2026Q3S2026-04-014000.000.000.00
2026Q3S2025-11-143000.000.000.00
2026Q3S2025-11-113000.000.000.00
2026Q3S2025-11-103000.000.000.00
2026Q3S2025-11-093000.000.000.00
2026Q3S2025-11-083000.000.000.00

Estimate history

EPS, annual-66.96-74.234-89.7476.319-62.775-57.351-78.791-11.42-3.26-2.7785
Period201720182019202020212022202320242025TTM
EPS, quarterly-13.167-8.189-5.04-3.219-1.004-0.589-0.776-0.725-0.688
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.91113.46919.886135.08223.02841.86720.968000
Period201720182019202020212022202320242025TTM
Sales, quarterly0.9912.5561.4552.56900000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.9071.0991.2981.3851.4861.4941.5132.5759.3819.381
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.5231.5241.5241.5259.3739.3799.3819.3819.381
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.0020.9741.8723.03135.0819.8913.47
Cost of Goods Sold Incl. D&A0.100.100.106.437.511.55---
Gross Profit-0.10-0.10-0.1014.5434.3521.47---
Selling, General and Administrative Excl. Other27.1126.6528.01136.03121.89110.56128.68130.7790.48
Research and Development18.0118.0123.65108.3891.7682.58107.74113.7175.24
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-27.20-26.75-28.11-121.50-87.53-89.085.38-111.68-77.38
Interest Expense0.000.008.470.600.000.000.000.000.00
Unusual Expense0.00-7.810.000.000.000.000.00--
Net Income Before Taxes-26.06-18.21-29.40-118.51-85.47-88.447.72-107.19-74.40
Income Taxes0.000.000.000.000.000.00-0.69-0.82-0.39
Consolidated Net Income-26.06-18.21-29.40-118.51-85.47-88.448.41-106.37-74.01
Net Income From Continuing Operations-26.06-18.21-29.40-118.51-85.47-88.448.41-106.37-74.01
Net Income-26.06-18.21-29.40-118.51-85.47-88.448.41-106.37-74.01
EPS (Recurring)-2.78-3.96-11.42-78.79-57.35-62.786.32-89.75-74.23
EPS (Basic, Before Extraordinaries)-2.78-2.46-11.42-78.79-57.35-62.776.39-89.75-74.23
EPS (Diluted)-2.78-3.26-11.42-78.79-57.35-62.776.32-89.75-74.23
EBITDA-27.11-26.65-28.01-121.24-85.86-87.536.40-110.88-77.01
Non-Operating Income (Expense)1.140.72-1.293.592.060.642.334.492.98
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.401.400.3213.2317.1116.708.557.526.64
Price To Earnings Ratio------186.98--
Price To Sales Ratio--3.911.9213.7626.835.3734.5734.64
Gross Margin---69.3282.0593.25---
Operating Margin----579.43-209.08-386.853.99-561.60-574.52
Net Margin----565.21-204.16-384.066.23-534.91-549.51
Shares Outstanding9.389.382.571.511.491.491.391.301.10
Market Capitalization18.8118.8127.9840.47577.10651.40754.57752.66514.12

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.002.571.462.56
Cost of Goods Sold Incl. D&A0.020.020.020.020.05--0.07
Gross Profit-0.02-0.02-0.02-0.02-0.05--2.48
Selling, General and Administrative Excl. Other6.617.037.565.918.824.967.007.76
Research and Development4.004.915.493.605.810.320.171.36
Other Operating Expense0.000.000.000.000.000.000.451.02
Operating Income-6.63-7.05-7.59-5.94-8.87-2.39-6.00-6.30
Interest Expense0.000.000.000.00-2.872.621.96
Unusual Expense0.000.000.000.00-12.750.00-0.124.98
Net Income Before Taxes-6.46-6.80-7.28-5.534.17-4.91-8.08-12.48
Income Taxes0.000.000.000.000.000.00-0.400.00
Consolidated Net Income-6.46-6.80-7.28-5.534.17-4.91-7.68-12.48
Net Income From Continuing Operations-6.46-6.80-7.28-5.534.17-4.91-7.68-12.48
Net Income-6.46-6.80-7.28-5.534.17-4.91-7.68-12.48
EPS (Recurring)-0.69-0.73-0.78-0.59-2.06-3.22-5.10-5.90
EPS (Basic, Before Extraordinaries)-0.69-0.73-0.78-0.590.51-3.22-5.04-8.19
EPS (Diluted)-0.69-0.73-0.78-0.59-1.00-3.22-5.04-8.19
EBITDA-6.61-7.03-7.56-5.91-8.82-2.39-6.00-6.23
Non-Operating Income (Expense)0.170.250.310.410.280.350.420.77
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.340.370.350.340.631.436.640.35
Price To Sales Ratio--15.7090.8129.983.063.921.94
Gross Margin-------97.14
Operating Margin------92.88-412.44-246.52
Net Margin------190.97-527.77-488.11
Shares Outstanding9.389.389.389.389.371.521.521.52
Market Capitalization18.8129.8340.34365.44218.3923.1927.9816.89

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments30.8131.61101.17145.81167.03180.93155.01161.7492.57
Short Term Receivables0.000.004.024.451.152.061.791.590.85
Inventories0.000.002.822.382.580.000.000.000.00
Other Current Assets0.730.078.1516.272.5212.088.864.801.64
Total Current Assets31.5431.69116.16168.91173.29195.06165.66168.1495.06
Net Property, Plant & Equipment0.200.308.191.983.605.123.740.881.18
Total Investments and Advances0.000.001.5011.3570.1670.9763.5721.800.77
Intangible Assets0.320.390.000.000.000.000.000.000.00
Other Assets0.022.830.000.000.000.000.000.000.00
Total Assets32.0735.20125.84182.24247.06271.16232.96190.8297.00
Short Term Debt Incl. Current Port. of LT Debt0.120.100.001.921.751.600.970.000.00
Accounts Payable3.222.1911.589.605.624.899.104.373.83
Other Current Liabilities7.718.0814.0111.9410.2411.9932.8336.084.68
Total Current Liabilities11.0410.3725.5923.4617.6218.4842.8940.458.51
Long Term Debt0.0930.4643.170.001.923.673.350.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.000.0016.751.72
Total Liabilities11.1340.8368.7623.4619.5322.1646.2557.1910.22
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.0085.500.000.000.000.000.000.000.00
Common Equity20.95-91.1357.09158.78227.52249.00186.71133.6386.78
Total Shareholders Equity20.95-5.6357.09158.78227.52249.00186.71133.6386.78
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity20.95-5.6357.09158.78227.52249.00186.71133.6386.78
Total Liabilities & Stockholders Equity32.0735.20125.84182.24247.06271.16232.96190.8297.00
Book Value Per Share2.23-35.3937.72106.25153.15179.74143.87121.6495.65
Tangible Book Value Per Share2.20-35.5437.72106.25153.15179.74143.87121.6495.65
Full-Time Employees1210551068480675537
Price to Book Ratio1.58-6.090.473.122.863.034.033.854.03
Return on Assets-47.99-36.51-76.94-39.82-34.133.34-50.20-51.43-72.28
Return on Equity-222.76-114.26-109.80-44.25-37.123.86-66.41-67.16-84.54
Return on Invested Capital-86.61-118.38-118.22-53.83-38.553.33-55.97-55.39-66.98
Quick Ratio2.863.064.437.109.6910.553.864.1611.18
Current Ratio2.863.064.547.209.8410.553.864.1611.18

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-26.06-18.21-29.40-118.51-85.47-88.448.41-106.37-74.01
Depreciation0.100.100.100.261.671.551.010.800.37
Other Funds (Non Cash)1.37-5.892.3616.0118.0021.54-7.54-4.568.12
Funds from Operations-24.60-24.01-26.95-102.25-65.81-65.351.88-110.13-65.52
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.430.518.6410.17-12.925.26-7.370.9143.22
Cash from Operating Activities-25.03-23.50-18.30-92.08-78.73-60.09-5.49-109.22-22.30
Capital Expenditures0.000.000.00-2.38-0.04-0.04-0.35-0.02-0.07
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.070.000.000.00
Purchase or Sale of Investments20.47-10.080.0045.84128.75-4.78-19.93-30.50-82.75
Purchase of Investments0.00-31.490.00-113.61-95.69-208.79-232.88-286.08-337.85
Sale Or Maturity of Investments20.4721.400.00159.44224.44204.01212.96255.58255.11
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities20.47-10.080.0043.46128.71-4.75-20.27-30.52-82.82
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.110.530.011.680.3146.6139.14142.60110.81
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.110.530.011.680.3146.6139.14142.60110.81
Proceedsfrom Stock Options0.000.000.001.120.0044.9738.45136.50106.62
Issuance or Reduction of Debt, Net0.000.0028.3036.470.000.000.000.000.00
Change in Long Term Debt0.000.0028.3036.470.000.000.000.000.00
Issuance of Long Term Debt0.000.0028.3036.470.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.4322.17-1.300.000.000.000.000.000.00
Other Financing Activities Uses-0.43-2.82-1.300.000.000.000.000.000.00
Cash from Financing Activities-0.3222.7027.0038.150.3146.6139.14142.60110.81
Net Change in Cash-4.88-10.888.70-10.4750.29-18.2313.382.865.69
Free Cash Flow-25.03-23.50-18.30-94.45-78.77-60.13-5.84-109.24-22.37
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments15.7724.9830.8136.4640.9934.22
Short Term Receivables0.000.000.000.000.002.24
Inventories0.000.000.000.000.000.90
Other Current Assets1.300.340.731.982.141.59
Total Current Assets17.0725.3331.5438.4443.1338.95
Net Property, Plant & Equipment0.140.170.200.220.250.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.290.310.320.340.350.00
Other Assets0.020.020.020.020.020.00
Total Assets17.5225.8232.0739.0243.7538.95
Short Term Debt Incl. Current Port. of LT Debt0.120.120.120.110.110.00
Accounts Payable4.644.623.224.082.420.00
Other Current Liabilities4.356.527.716.858.141.20
Total Current Liabilities9.1111.2611.0411.0410.681.20
Long Term Debt0.020.050.090.120.1445.82
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities9.1311.3111.1311.1510.8247.02
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity8.3814.5120.9527.8732.93-8.07
Total Shareholders Equity8.3814.5120.9527.8732.93-8.07
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity8.3814.5120.9527.8732.93-8.07
Total Liabilities & Stockholders Equity17.5225.8232.0739.0243.7538.95
Book Value Per Share0.891.552.232.973.51-5.30
Tangible Book Value Per Share0.861.512.202.933.48-5.30
Full-Time Employees--121211-
Price to Book Ratio1.581.421.4511.09-4.41-2.87
Return on Assets-85.08-47.68-35.68-30.87-35.95-69.86
Return on Equity-126.19-480.07-165.61-97.61-93.85-414.88
Return on Invested Capital-76.83-46.73-34.59-19.7512.60-13.00
Quick Ratio1.872.252.863.484.0431.73
Current Ratio1.872.252.863.484.0432.48

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-6.46-6.80-7.28-5.53-0.51-4.91
Depreciation0.020.020.020.020.050.00
Other Funds (Non Cash)0.340.350.340.33-10.854.29
Funds from Operations-6.09-6.42-6.91-5.17-11.31-0.61
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.130.571.230.912.44-4.08
Cash from Operating Activities-9.23-5.86-5.68-4.26-8.87-4.69
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments5.144.985.005.35-20.430.00
Purchase of Investments0.000.000.000.00-31.490.00
Sale Or Maturity of Investments5.144.985.005.3511.050.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities5.144.985.005.35-20.430.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.000.110.420.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.000.110.420.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.00-1.011.01
Change in Long Term Debt0.000.000.000.00-1.011.01
Issuance of Long Term Debt0.000.000.000.00-2.502.50
Reduction of Long Term Debt0.000.000.000.001.49-1.49
Net Financing Active Other Cash Flow0.000.000.00-0.4322.600.00
Other Financing Activities Uses0.000.000.00-0.43-2.390.00
Cash from Financing Activities0.000.000.00-0.3222.021.01
Net Change in Cash-4.09-0.88-0.680.77-7.28-3.69
Free Cash Flow-9.23-5.86-5.68-4.26-8.87-4.69

Revenue breakdown

Clinical compound revenue2024: 84.00K
Collaborative revenue2024: 2.09M
Commercial supply revenue2024: 640.00K
Other revenue (non-cash)2024: 4.33M
United States2024: 7.14M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.98%0.3M10.0M186.03K
2026-10-153.74%0.4M10.0M310.31K
2026-09-302.24%0.2M10.0M2.25M
2026-09-152.55%0.3M10.0M2.35M
2026-08-313.06%0.3M8.7M2.30M
2026-08-142.00%0.2M8.7M2.32M
2026-07-314.32%0.3M6.1M2.29M
2026-07-158.93%0.5M6.1M2.17M
2026-06-308.35%0.5M6.1M158.10K
2026-06-156.55%0.4M6.1M51.87K
2026-05-297.17%0.4M6.1M49.14K
2026-05-158.06%0.5M6.1M47.63K
2026-04-307.77%0.5M6.6M50.50K
2026-04-158.46%0.6M6.6M53.49K
2026-03-319.98%0.7M6.6M62.57K
2026-03-1310.21%0.7M6.6M83.87K
2026-02-279.72%0.6M6.6M94.98K
2026-02-1311.27%0.7M6.6M106.15K
2026-01-3010.45%0.7M6.4M127.00K
2026-01-158.63%0.5M6.4M193.93K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.000.10-53.000.00---
call5.000.000.000.07-52.000.00---
call7.500.000.000.05-2.000.00---
put2.500.000.000.00-0.000.00---
put5.000.000.000.00-1.000.00---
put7.500.000.006.70-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-07-308-KCurrent report2026-07-30SEC
2026-07-178-KCurrent report2026-07-17SEC
2026-07-17424B5SEC
2026-07-078-KCurrent report2026-07-07SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-118-KCurrent report2026-06-09SEC
2026-05-13EFFECTEffectiveness filing by commission orderSEC
2026-05-12EFFECTEffectiveness filing by commission orderSEC
2026-05-08POS AMPost-effective amendment to a registration statement that is not immediately effective upon filingSEC
2026-05-08CORRESPSEC
2026-05-0810-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-088-KCurrent report2026-05-08SEC
2026-05-07UPLOADUpload SubmissionSEC
2026-05-01S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-04-23ARSAnnual report to security holders. 2025-12-31SEC
2026-04-23DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-23DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-09SEC
2026-04-01S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-04-01POS EXPost-effective amendment filed solely to add exhibits to a registration statementSEC
2026-04-01424B3SEC
2026-03-3110-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-318-KCurrent report2026-03-31SEC
2026-03-06424B3SEC
2026-03-068-KCurrent report2026-03-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Slate Path Capital LP7.51%
VANGUARD CAPITAL MANAGEMENT LLC3.67%
AMERICAN FINANCIAL GROUP INC2.38%
SILVERCREST ASSET MANAGEMENT GROUP LLC1.08%
BlackRock, Inc.1.02%
RENAISSANCE TECHNOLOGIES LLC0.97%
GEODE CAPITAL MANAGEMENT, LLC0.90%
MORGAN STANLEY0.83%
Duncan Williams Asset Management, LLC0.67%
VANGUARD FIDUCIARY TRUST CO0.48%

Funds

Fund% owned
Fidelity Small Cap Index Fund0.63%
Fidelity Extended Market Index Fund0.54%
Schwab Small-Cap Index Fund0.13%
Fidelity Total Market Index Fund0.11%
iShares Russell 2000 ETF0.09%
Fidelity Series Total Market Index Fund0.09%
Nuveen Small Cap Blend Index Fund0.06%
iShares Russell 2000 Value ETF0.03%
Fidelity Nasdaq Composite Index Fund0.03%
Global X Russell 2000 ETF0.02%

OakChart. TVRD. Cached 15 minutes.

Some panels did not load: insider.